This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research aims to develop novel physiological markers of high-risk labored breathing to provide advance warning of respiratory failure. The $807,067 award to the Rector & Visitors of the University of Virginia will fund a 5-year study to quantify respiratory kinematics using a new wearable sensor technology called ARK (Analysis of Respiratory Kinematics). The...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $1,160,157 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Liberandum Technologies, Inc. to develop and test a bidirectional synchronous flow-controlled ventilation system called "VentSafe" to improve oxygenation and ventilation in patients with Acute Respiratory Distress Syndrome (ARDS). The goal of this Phase 1 Small Business Innovation Research (SBIR) project is to overcome the limitations of...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,107,276 to Lasarrus Clinic And Research Center Inc. to develop a mobile health system for remote monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD). The project aims to enhance patient adherence to remote monitoring and early symptom recognition, in order to reduce COPD readmissions and healthcare costs. The system utilizes a wearable...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,231,242 to develop and validate a diagnostic tool called Deep Learning-Enhanced Transmembranous Electromyography (DL-TMEMG) for detecting obstructive sleep apnea (OSA). The overarching objective is to create a convenient, accurate, and widely-usable point-of-care device for OSA diagnosis. In Phase 1, the project aims to establish the...
This federal Project Grant award of $371,021 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Makani Science Inc., a small business located in Irvine, California. The goal of this 2-year award (4/9/2025 - 2/28/2027) is to develop an apnea monitoring platform capable of accurately identifying the major types of apnea of prematurity (central, obstructive, and mixed) in premature newborns. The proposed work...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $117,750 to the Ann & Robert H Lurie Children's Hospital of Chicago to develop and validate the use of wireless biosensors and a portable capnograph device for remote patient monitoring of children on long-term invasive home mechanical ventilation. The project aims to address limitations of the hospital's current hand-collected vital sign data approach by...
The National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $863,328 Project Grant to Aquillius Corp to develop a wearable graphene respiratory sensor for early detection and monitoring of asthma. The sensor is intended to provide real-time continuous monitoring and measurement of pulmonary functions, particularly for children, to improve asthma diagnosis, treatment, and patient care. The Phase I feasibility studies will focus on...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $295,924 to Convergent Engineering, Inc. to develop a prototype decision support system for personalized mechanical ventilation care. The system aims to simplify the use of esophageal pressure measurements to optimize ventilator settings and prevent complications for ventilated patients. The project has two key objectives: 1) Building a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $300,000 to develop a hand-held smart sensor system that can noninvasively detect exhaled volatile organic compound (VOC) biomarkers for predicting pulmonary exacerbations in children with cystic fibrosis. The goal is to leverage machine learning to identify a breath-based biosignature for pulmonary exacerbations, design and test...
ADVANCED PREDICTION OF EMERGING RESPIRATORY DECLINE WITH THE LINSHOM CONTINUOUS PREDICTIVE RESPIRATORY SENSOR (CPRS) - ABSTRACT: THIS FAST-TRACK SBIR APPLICATION WILL FUND AND ENABLE A NEW APPROACH TO RESPIRATORY MONITORING, CONTINUOUS PREDICTIVE RESPIRATORY MONITORING (CPRM), THAT STANDS TO REDUCE MORBIDITY AND MORTALITY DUE TO RESPIRATORY COMPROMISE, WHILE REDUCING HEALTH CARE SYSTEM COSTS. CURRENT DEVICES AND SYSTEMS (HUMAN AND MACHINE) FOR RESPIRATORY MONITORING ARE RESPONSIVE BY SOUNDING A WARNING ALARM WHEN A PATIENT REACHES A THRESHOLD OF A PHYSIOLOGIC PARAMETER (I.E. SPO2, ETCO2) AND THE PATIENT IS CURRENTLY OR HAS BEEN IN DISTRESS. TECHNOLOGICAL LIMITATIONS HAVE PREVENTED THE FIELD FROM MOVING FURTHER IN ITS ABILITY TO PREDICT PATIENT DECLINE SO THAT HEALTH CARE PROVIDERS (HCPS) ARE ABLE TO INTERVENE AND STOP OR CORRECT RESPIRATORY DECLINE. LINSHOM HAS DEVELOPED A SIMPLE, INEXPENSIVE SOLUTION FOR CONTINUOUS MONITORING OF RESPIRATORY FUNCTIONS INCLUDING RR, TV, MV, I:E RATIO, AND APNEA DETECTION. LINSHOM'S 510K FDA-CLEARED CONTINUOUS PREDICTIVE RESPIRATORY SENSOR (CPRS) SOLVES EXISTING UNMET NEEDS MENTIONED ABOVE WITH A SMALL, PORTABLE, AND INEXPENSIVE SENSOR AND MONITOR THAT TRACKS RR, TV, MV, SECONDS SINCE LAST BREATH (SSLB), AND I:E RATIO IN REAL TIME. THESE PARAMETERS ARE CRUCIAL FOR MONITORING OF PATIENTS SUFFERING FROM BOTH ACUTE AND CHRONIC RESPIRATORY ILLNESS. UNLIKE OTHER RESPIRATORY MONITORING TECHNOLOGIES, LINSHOM OFFERS AN OPERATING ROOM-QUALITY RESPIRATORY PROFILE AT THE PATIENT BEDSIDE, WHICH ALLOWS HEALTH CARE PROVIDERS TO PROMPTLY DIAGNOSE EMERGING RESPIRATORY DECLINE AND INTERVENE WITH APPROPRIATE MEDICAL CARE. TIMELY INTERVENTION SHOULD REDUCE MORBIDITY AND MORTALITY AND RESULT IN SIGNIFICANTLY IMPROVED CARE FOR THE PATIENT AND LARGE SAVINGS FOR THE HEALTH CARE SYSTEM VIA REDUCTION IN RAPID RESPONSE ACTIVATION AND ICU TRANSFERS. LINSHOM'S UNIQUE ABILITY TO PROVIDE TV (AND THUS MV) IN THE NON-INTUBATED PATIENT CREATES A PROFILE OF PATIENT RESPIRATORY STATUS PREVIOUSLY NOT AVAILABLE OUTSIDE OF THE OR OR ICU (AND ONLY IN INTUBATED PATIENTS). IN THIS FASTTRACK SBIR WE WILL I) GENERATE CLINICAL DATA PROVING LINSHOM CPRM'S ABILITY TO DETECT (PREDICT) A RESPIRATORY DEPRESSION EPISODE (RDE) BEFORE CURRENT STANDARD OF CARE AND DEVICES, II.) DETERMINE OPTIMAL TIMES TO SET EARLY WARNING ALARMS (MAXIMIZING SENSITIVITY AND SPECIFICITY) SUCH THAT HCPS CAN INTERVENE SOONER THAN CURRENT PRACTICE AND AVOID MORBIDITY AND MORTALITY DUE TO RESPIRATORY FAILURE, AND IV.) REDESIGN THE CPRS INTO A MINIATURIZED CHIP BASED DEVICE ENABLING THE LINSHOM CPRM TO REACH MORE PATIENTS BY ENABLING NASAL CANNULA (AND EVENTUALLY A HOME MONITOR) INTEGRATION.